Jardiance Outcomes-Based Contracting Push Underway, Armed With CV Claim
Executive Summary
Boehringer Ingelheim agreement with data analytics firm Inovalon and health care consultancy Avalere will support outcomes-based coverage deals.
You may also be interested in...
Pricing Pressure On Drugs To Intensify As Some Enrollee Cost-Shifting Measures Plateau – PwC
Employers’ may also look more at pitting their health plan vendors against each other for cost-saving coverage, meaning drug makers face more pressure to negotiate reimbursement and other new approaches with health plans, a PwC report suggests.
Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too
US labeling for Boehringer/Lilly's SGLT-2 inhibitor empagliflozin includes results from MACE primary endpoint and its individual components in the EMPA-REG trial, but indication statement is limited to CV risk reduction benefit.
Jardiance's Label Expansion Will Change Diabetes Management
US approval of the first cardiovascular label expansion for an anti-diabetic medicine will mark a shift in disease management, says Datamonitor Healthcare analyst Kevin Shannon.